Immunological methods for quantifying free and total serum IgE levels in allergy patients receiving omalizumab (Xolair) therapy.

@article{Hamilton2005ImmunologicalMF,
  title={Immunological methods for quantifying free and total serum IgE levels in allergy patients receiving omalizumab (Xolair) therapy.},
  author={Robert M. Hamilton and Gregory Vincent Marcotte and S S Saini},
  journal={Journal of immunological methods},
  year={2005},
  volume={303 1-2},
  pages={81-91}
}
Omalizumab (humanized-IgG1 anti-human IgE Fc, Xolair) complexes circulating IgE, blocking IgE binding to high affinity epsilon Fc receptors (FcepsilonR1) on mast cells and basophils. Free (non-Omalizumab bound) IgE levels in serum are a measure of effective Omalizumab dosing. The goal of this study was to quantify free (non-Omalizumab-complexed) and total serum IgE levels in asthma patients on Xolair. The concentration of (non-Omalizumab bound) free IgE in human serum was measured using a solid… CONTINUE READING

From This Paper

Topics from this paper.

Citations

Publications citing this paper.
Showing 1-10 of 36 extracted citations

Clinical and pharmacoeconomic aspects of omalizumab: a 4-year follow-up.

Therapeutic advances in respiratory disease • 2012
View 9 Excerpts
Highly Influenced

A humanized mouse model of anaphylactic peanut allergy.

The Journal of allergy and clinical immunology • 2017
View 1 Excerpt

Similar Papers

Loading similar papers…